Kristjánsdóttir Ingibjörg, Thorvaldsen Tonje, Lund Lars H
Karolinska Institutet, Department of Medicine, Stockholm, Sweden; and Karolinska University Hospital, Heart and Vascular Theme Stockholm, Sweden.
Card Fail Rev. 2020 Sep 28;6:e25. doi: 10.15420/cfr.2019.18. eCollection 2020 Mar.
Hospitalisation for acute heart failure (AHF) is associated with high mortality and high rehospitalisation rates. In the absence of evidence-based therapy, treatment is aimed at stabilisation and symptom relief. The majority of AHF patients have signs and symptoms of fluid overload, and, therefore, decongestion is the number one treatment goal. Diuretics are the cornerstone of therapy in AHF, but the treatment effect is challenged by diuretic resistance and poor diuretic response throughout the spectrum of chronic to worsening to acute to post-worsening HF. Adequate dosing and monitoring and evaluation of diuretic effect are important for treatment success. Residual congestion at discharge is a strong predictor of worse outcomes. Therefore, achieving euvolaemia is crucial despite transient worsening renal function.
急性心力衰竭(AHF)住院与高死亡率和高再住院率相关。在缺乏循证治疗的情况下,治疗旨在实现病情稳定和症状缓解。大多数AHF患者有液体过载的体征和症状,因此,消除充血是首要治疗目标。利尿剂是AHF治疗的基石,但在从慢性到病情恶化、急性发作到病情恶化后心力衰竭的整个范围内,利尿剂抵抗和利尿反应不佳对治疗效果构成挑战。利尿剂的适当给药以及对利尿效果的监测和评估对治疗成功很重要。出院时仍有充血是预后较差的有力预测指标。因此,尽管肾功能会短暂恶化,但实现血容量正常至关重要。